NEW YORK, NY / ACCESSWIRE / March 16, 2022 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
Tal Education Group (NYSE:TAL)
CONTACT JAKUBOWITZ ABOUT TAL:
https://claimyourloss.com/securities/tal-education-group-loss-submission-form/?id=24778&from=1
Class Period: April 26, 2018 – July 22, 2021
Lead Plaintiff Deadline: April 5, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) TAL’s revenue and operational growth was the result of deceptive marketing tactics and illicit business practices that flouted Chinese laws, regulations and policies, and exposed the Company to an extreme risk that more draconian measures would be imposed on the Company; (b) TAL had engaged in misleading and fraudulent advertising practices, including the provision of false and misleading discount information designed to obfuscate the true cost of the Company’s programs to its customers, the creation of fake customer reviews designed to fraudulently lure new customers to TAL programs, the misrepresentation of teacher qualifications and course qualities, and the marketing of rigged promotional events; (c) TAL had defied Chinese policies designed to alleviate the burden imposed by tutoring services on students and their families, including by imposing hefty advances and recurring debt payments on course enrollees, by offering courses designed to give affluent students unfair advantages, by holding courses outside of allowable tutoring hours, and by linking for-profit courses to government-mandated schooling; (d) as a result of the foregoing, TAL was subject to an extreme undisclosed risk of adverse enforcement actions, regulatory fines and penalties, and the imposition of new rules and regulations adverse to the Company’s business and financial interests; and (e) as a result of the foregoing, TAL’s historical growth was not sustainable or the result of legitimate business tactics as represented, and defendants’ positive statements about the Company’s business, operations, and prospects were materially false and misleading and lacked a reasonable factual basis.
Telos Corporation (NASDAQ:TLS)
CONTACT JAKUBOWITZ ABOUT TLS:
https://claimyourloss.com/securities/telos-corporation-loss-submission-form/?id=24778&from=1
Class Period : November 19, 2020 – November 12, 2021
Lead Plaintiff Deadline : April 8, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Transportation Security Administration (“TSA”) and Centers for Medicare and Medicaid Services (“CMS”) contracts, which constituted a majority of the Company’s future revenues, were not on track to commence as represented at the end of 2021 and in 2022; (2) Defendants lacked a reasonable basis and sufficient visibility to provide and affirm the Company’s 2021 guidance in the face of the uncertainty surrounding the TSA and CMS contracts; (3) COVID-19- and hacking scandal-related headwinds were throwing off the timing for performance of the TSA and CMS contracts and their associated revenues; (4) as a result, the guidance provided by Defendants was not in fact “conservative”; (5) as a result of the delays, Telos would be forced to dramatically reduce its revenue estimates; and (6) as a result of the foregoing, Defendants’ statements about Telos’ business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis.
Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
CONTACT JAKUBOWITZ ABOUT FENC:
https://claimyourloss.com/securities/fennec-pharmaceuticals-inc-loss-submission-form-2/?id=24778&from=1
Class Period: May 28, 2021 – November 26, 2021
Lead Plaintiff Deadline: April 11, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Fennec had not successfully remediated, and overstated its efforts to remediate, issues with the manufacturing facility of its drug product manufacturer for PEDMARK, a new compound developed to reduce the incidence of hearing loss in children undergoing chemotherapy; (ii) as a result, the Food and Drug Administration likely to approve the Resubmitted Pedmark New Drug Application (“NDA”); (iii) accordingly, the regulatory and commercial prospects of the Resubmitted Pedmark NDA were overstated; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE: Jakubowitz Law
View source version on accesswire.com:
https://www.accesswire.com/693359/LAWSUITS-FILED-AGAINST-TAL-TLS-and-FENC–Jakubowitz-Law-Pursues-Shareholder-Claims